Mattia Boeri

4.5k total citations · 3 hit papers
54 papers, 2.9k citations indexed

About

Mattia Boeri is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mattia Boeri has authored 54 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cancer Research, 28 papers in Molecular Biology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mattia Boeri's work include MicroRNA in disease regulation (21 papers), Cancer-related molecular mechanisms research (21 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Mattia Boeri is often cited by papers focused on MicroRNA in disease regulation (21 papers), Cancer-related molecular mechanisms research (21 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Mattia Boeri collaborates with scholars based in Italy, United States and United Kingdom. Mattia Boeri's co-authors include Gabriella Sozzi, Ugo Pastorino, Carla Verri, Davide Conte, Luca Roz, Alfonso Marchianò, Nicola Sverzellati, Stefano Sestini, Paola Suatoni and Federica Facchinetti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mattia Boeri

51 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer

2011 568 citations Mattia Boeri, Carla Verri et al. profile →
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy

2019 359 citations Ugo Pastorino, Mario Silva et al. Annals of Oncology profile →
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

2018 357 citations Mattia Boeri, Gabriella Sozzi et al. Journal of Thoracic Oncology profile →

Peers

Mattia Boeri

PRM

ONCOL

RNMI

Peter Meldgaard Denmark

Simona Coco Italy

Yoshimasa Maniwa Japan

Bo Chen China

John C. English Canada

María D. Lozano Spain

Likun Hou China

Stefanie Hammer Germany

Athina Markou Greece

Ning Li China

Peter Meldgaard Denmark

Mattia Boeri

858 ×0.6

888 ×0.7

1.1k ×1.0

PRM

890 ×1.5

ONCOL

259 ×0.6

RNMI

Citations per year, relative to Mattia Boeri Mattia Boeri (= 1×) peers Peter Meldgaard

Countries citing papers authored by Mattia Boeri

Since Specialization

Citations

This map shows the geographic impact of Mattia Boeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mattia Boeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mattia Boeri more than expected).

Fields of papers citing papers by Mattia Boeri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mattia Boeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mattia Boeri. The network helps show where Mattia Boeri may publish in the future.

Co-authorship network of co-authors of Mattia Boeri

This figure shows the co-authorship network connecting the top 25 collaborators of Mattia Boeri. A scholar is included among the top collaborators of Mattia Boeri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mattia Boeri. Mattia Boeri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Proto, Claudia, Giuseppe Lo Russo, Arsela Prelaj, et al.. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 9(9). e2400790–e2400790. 1 indexed citations

Boeri, Mattia, Federica Sabia, Roberta Eufrasia Ledda, et al.. (2024). Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial. The Lancet Regional Health - Europe. 46. 101070–101070. 6 indexed citations

Moro, Massimo, Orazio Fortunato, Giulia Bertolini, et al.. (2022). MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway. Pharmaceuticals. 15(3). 297–297. 19 indexed citations

Fortunato, Orazio, Veronica Huber, Agata Cova, et al.. (2022). Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening. Cancer Epidemiology Biomarkers & Prevention. 31(11). 2020–2029. 3 indexed citations

Pastorino, Ugo, Federica Sabia, Luigi Rolli, et al.. (2022). Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial. Journal of Thoracic Oncology. 17(11). 1276–1286. 23 indexed citations

Pastorino, Ugo, Mattia Boeri, Stefano Sestini, et al.. (2022). Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Annals of Oncology. 33(4). 395–405. 60 indexed citations

Montomoli, Emanuele, Giovanni Apolone, Alessandro Manenti, et al.. (2021). Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting. Viruses. 14(1). 61–61. 9 indexed citations

Milione, Massimo, Mattia Boeri, Anna Cantarutti, et al.. (2020). Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. Cancers. 12(7). 1828–1828. 1 indexed citations

Boeri, Mattia, Massimo Milione, Claudia Proto, et al.. (2019). Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clinical Cancer Research. 25(7). 2166–2173. 64 indexed citations

10.

Gasparini, Patrizia, Orazio Fortunato, Loris De Cecco, et al.. (2019). Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma. Cancers. 11(9). 1380–1380. 16 indexed citations

11.

Sozzi, Gabriella, Mattia Boeri, & Ugo Pastorino. (2019). MS18.02 Circulating Nucleic Acid Biomarkers. Journal of Thoracic Oncology. 14(10). S192–S193. 1 indexed citations

12.

Boeri, Mattia, Massimo Milione, Diego Signorelli, et al.. (2018). MA04.07 MicroRNA-Based Liquid Biopsy Combines with PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients. Journal of Thoracic Oncology. 13(10). S368–S369. 2 indexed citations

13.

Moro, Massimo, Giulia Bertolini, Roberto Caserini, et al.. (2017). Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. Scientific Reports. 7(1). 6689–6689. 34 indexed citations

14.

Sestini, Stefano, Mattia Boeri, Alfonso Marchianò, et al.. (2017). [Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test].. PubMed. 40(1 Suppl 1). 42–50. 6 indexed citations

15.

Fortunato, Orazio, Carla Verri, Ugo Pastorino, Gabriella Sozzi, & Mattia Boeri. (2016). MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. SHILAP Revista de lepidopterología. 5(3). 18–18. 8 indexed citations

16.

Boeri, Mattia, Gabriella Sozzi, & Ugo Pastorino. (2016). Clinical relevance of circulating microRNAs as lung cancer biomarkers. Journal of Thoracic Oncology. 11(2). S2–S2. 1 indexed citations

17.

Pastorino, Ugo, Roberto Boffi, Alfonso Marchianò, et al.. (2016). Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants. Journal of Thoracic Oncology. 11(5). 693–699. 35 indexed citations

18.

Sozzi, Gabriella, Mattia Boeri, Marta Rossi, et al.. (2014). Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study. Journal of Clinical Oncology. 32(8). 768–773. 318 indexed citations

19.

Fortunato, Orazio, Mattia Boeri, Carla Verri, et al.. (2014). Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules. 19(3). 3038–3054. 66 indexed citations

20.

Fortunato, Orazio, Mattia Boeri, Massimo Moro, et al.. (2014). Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death and Disease. 5(12). e1564–e1564. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact